Aimovig and Ajovy Comparison

Aimovig®(erenumab-aooe)	Ajovy®(fremanezumab)
Prescription Only Aimovig is a prescription medication that adults can self-inject once a month under the skin to prevent migraine headaches. The most common side effects are injection site...	Prescription Only Ajovy is a prescription medication that can be self-injected once a month or once every three months under the skin to prevent migraine headaches. The most commonly reported side...
Administration
Subcutaneous . Learn more.	Subcutaneous. Learn more.
Dosing
70 mg once monthly or 140 mg once monthly (for some patients). Learn more.	225 mg monthly or 675 mg every 3 months (as three consecutive injections of 225 mg each). Learn more.
Latin Shorthand
70 mg/mo or 140 mg/mo. Learn more.	225 mg/mo or 675 mg q3mo. Learn more.
Out-Of-Pocket Costs With Copay Card
$5. Learn more.	$5. Learn more.
Annual Cap
Patient specific maximum benefit.. Learn more.	Patient specific maximum benefit.. Learn more.
Assistance Expiration
Calendar year. Learn more.	12/31/2023. Learn more.
Generics
No lower-cost generic available	No lower-cost generic available
Adverse Reactions
The most common adverse reactions in AIMOVIG clinical studies (occurring in at least 3% of treated patients and more often than placebo) are injection site reactions and constipation. . Learn more.	The most common adverse reactions (≥5% and greater than placebo) were injection site reactions.. Learn more.
Mechanism of Actions (MoA)
CGRP Antagonist . Learn more.	CGRP Antagonist. Learn more.
Special Populations
Is it safe to use AIMOVIG during pregnancy? There are no adequate data on the developmental risk associated with the use of AIMOVIG in pregnant women. No adverse effects on offspring were observed when pregnant monkeys were administered erenumab-aooe throughout gestation. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2%-4% and 15%-20%, respectively. The estimated rate of major birth defects (2.2%-2.9%) and miscarriage (17%) among deliveries to women with migraine are similar to rates reported in women without migraine. Healthcare providers are advised to consider the potential risks and benefits of AIMOVIG for pregnant women. Is there any clinical consideration for women with migraine during pregnancy? Published data have suggested that women with migraine may be at increased risk of preeclampsia and gestational hypertension during pregnancy. What animal data is available for AIMOVIG use during pregnancy? In a study in which female monkeys were administered erenumab-aooe (0 or 50 mg/kg) twice weekly by subcutaneous injection throughout pregnancy (gestation day 20-22 to parturition), no adverse effects on offspring were observed. Serum erenumab-aooe exposures (AUC) in pregnant monkeys were approximately 20 times that in humans at a dose of 140 mg once monthly. Is it safe to use AIMOVIG while breastfeeding? There are no data on the presence of erenumab-aooe in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for AIMOVIG and any potential adverse effects on the breastfed infant from AIMOVIG or from the underlying maternal condition. Is AIMOVIG safe for use in pediatric patients? Safety and effectiveness in pediatric patients have not been established. Is AIMOVIG safe for use in geriatric patients? Clinical studies of AIMOVIG did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.	Is there a pregnancy exposure registry for AJOVY? Yes, there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to AJOVY during pregnancy. Healthcare providers are encouraged to register pregnant patients, or pregnant women may enroll themselves in the registry by calling 1-833-927-2605 or visiting www.tevamigrainepregnancyregistry.com. What is the risk associated with the use of AJOVY during pregnancy? There are no adequate data on the developmental risk associated with the use of AJOVY in pregnant women. AJOVY has a long half-life, which should be taken into consideration for women who are pregnant or plan to become pregnant while using AJOVY. However, administration of fremanezumab-vfrm (the active ingredient in AJOVY) to rats and rabbits during the period of organogenesis or to rats throughout pregnancy and lactation at doses resulting in plasma levels greater than those expected clinically did not result in adverse effects on development. What is the estimated background risk of major birth defects and miscarriage for the indicated population? The estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively, for the U.S. general population. The estimated rate of major birth defects and miscarriage among deliveries to women with migraine are similar to rates reported in women without migraine. Is AJOVY safe to use during lactation? There are no data on the presence of fremanezumab-vfrm (the active ingredient in AJOVY) in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for AJOVY and any potential adverse effects on the breastfed infant from AJOVY or from the underlying maternal condition. Is AJOVY safe and effective for use in pediatric patients? Safety and effectiveness in pediatric patients have not been established. Is there any information on the use of AJOVY in geriatric patients? Clinical studies of AJOVY did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.

Aimovig®(erenumab-aooe)

Ajovy®(fremanezumab)

Prescription Only

Aimovig is a prescription medication that adults can self-inject once a month under the skin to prevent migraine headaches. The most common side effects are injection site...

Prescription Only

Ajovy is a prescription medication that can be self-injected once a month or once every three months under the skin to prevent migraine headaches. The most commonly reported side...

Dosage & Administration

Administration

Subcutaneous . Learn more.

Subcutaneous. Learn more.

Dosing

70 mg once monthly or 140 mg once monthly (for some patients). Learn more.

225 mg monthly or 675 mg every 3 months (as three consecutive injections of 225 mg each). Learn more.

Latin Shorthand

70 mg/mo or 140 mg/mo. Learn more.

225 mg/mo or 675 mg q3mo. Learn more.

Financial Assistance

Out-Of-Pocket Costs With Copay Card

$5. Learn more.

Annual Cap

Patient specific maximum benefit.. Learn more.

Assistance Expiration

Calendar year. Learn more.

12/31/2023. Learn more.

Generics

No lower-cost generic available

Physician Advisory

Adverse Reactions

The most common adverse reactions in AIMOVIG clinical studies (occurring in at least 3% of treated patients and more often than placebo) are injection site reactions and constipation. . Learn more.

The most common adverse reactions (≥5% and greater than placebo) were injection site reactions.. Learn more.

Mechanism of Actions (MoA)

CGRP Antagonist . Learn more.

CGRP Antagonist. Learn more.

Special Populations

Is it safe to use AIMOVIG during pregnancy?

There are no adequate data on the developmental risk associated with the use of AIMOVIG in pregnant women. No adverse effects on offspring were observed when pregnant monkeys were administered erenumab-aooe throughout gestation. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2%-4% and 15%-20%, respectively. The estimated rate of major birth defects (2.2%-2.9%) and miscarriage (17%) among deliveries to women with migraine are similar to rates reported in women without migraine. Healthcare providers are advised to consider the potential risks and benefits of AIMOVIG for pregnant women.

Is there any clinical consideration for women with migraine during pregnancy?

Published data have suggested that women with migraine may be at increased risk of preeclampsia and gestational hypertension during pregnancy.

What animal data is available for AIMOVIG use during pregnancy?

In a study in which female monkeys were administered erenumab-aooe (0 or 50 mg/kg) twice weekly by subcutaneous injection throughout pregnancy (gestation day 20-22 to parturition), no adverse effects on offspring were observed. Serum erenumab-aooe exposures (AUC) in pregnant monkeys were approximately 20 times that in humans at a dose of 140 mg once monthly.

Is it safe to use AIMOVIG while breastfeeding?

There are no data on the presence of erenumab-aooe in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for AIMOVIG and any potential adverse effects on the breastfed infant from AIMOVIG or from the underlying maternal condition.

Is AIMOVIG safe for use in pediatric patients?

Safety and effectiveness in pediatric patients have not been established.

Is AIMOVIG safe for use in geriatric patients?

Clinical studies of AIMOVIG did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

Is there a pregnancy exposure registry for AJOVY?

Yes, there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to AJOVY during pregnancy. Healthcare providers are encouraged to register pregnant patients, or pregnant women may enroll themselves in the registry by calling 1-833-927-2605 or visiting www.tevamigrainepregnancyregistry.com.

What is the risk associated with the use of AJOVY during pregnancy?

There are no adequate data on the developmental risk associated with the use of AJOVY in pregnant women. AJOVY has a long half-life, which should be taken into consideration for women who are pregnant or plan to become pregnant while using AJOVY. However, administration of fremanezumab-vfrm (the active ingredient in AJOVY) to rats and rabbits during the period of organogenesis or to rats throughout pregnancy and lactation at doses resulting in plasma levels greater than those expected clinically did not result in adverse effects on development.

What is the estimated background risk of major birth defects and miscarriage for the indicated population?

The estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively, for the U.S. general population. The estimated rate of major birth defects and miscarriage among deliveries to women with migraine are similar to rates reported in women without migraine.

Is AJOVY safe to use during lactation?

There are no data on the presence of fremanezumab-vfrm (the active ingredient in AJOVY) in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for AJOVY and any potential adverse effects on the breastfed infant from AJOVY or from the underlying maternal condition.

Is AJOVY safe and effective for use in pediatric patients?

Safety and effectiveness in pediatric patients have not been established.

Is there any information on the use of AJOVY in geriatric patients?

Clinical studies of AJOVY did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.

Aimovig® Alternatives